At the last check on Friday, TRxADE HEALTH Inc.’s (NASDAQ:MEDS) stock was up $3.04, moving up 39.79 percent to $10.68. The average number of shares traded per day over the past five days has been 1,754,624 shares. 4 times new highs have been achieved over the past 5 days, with a $4.39 gain in that time frame. In the last twenty days, the average volume was 485,696, while in the previous 50 days, it was 846,348.
Since last month, MEDS stock rose 24.19%. Shares of the company fell to $6.30 on 08/29/23, the lowest level in the past month. A 52-week high of $22.80 was reached on 06/26/23 after having rallying from a 52-week low of $3.77. Since the beginning of this year, MEDS’s stock price has risen by 76.85% or $5.28, and marked a new high 4 times. However, the stock has declined by -53.16% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, TRxADE HEALTH Inc.’s quick ratio stood at 0.50, while its current ratio was 0.50, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 54.30% percent. In the year ended June 29, EBITDA margin amounted to -21.98%, whereas operating margins totaled -29.40%. Based on annual data, MEDS earned $5.45 million in gross profit and brought in $11.45 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MEDS’s revenue fell -40.89% to $2.25 million during the quarter, while net income inched up to $2.25 million. While analysts expected TRxADE HEALTH Inc. to report -$0.75 quarterly earnings, the actual figure was -$2.9 per share, beating the consensus estimate by -286.70%. During the quarter, the company generated -$0.29 million in EBITDA. The liabilities of TRxADE HEALTH Inc. were 5.04 million at the end of its most recent quarter ended June 29, and its total debt was $0.99 million. The value of shareholders’ equity is $1.25 million.
Technical Picture
This quick technical analysis looks at TRxADE HEALTH Inc.’s (MEDS) price momentum. With a historical volatility rate of 218.27%, the RSI 9-day stood at 76.70% on 31 August.
With respect to its five-day moving average, the current TRxADE HEALTH Inc. price is up by +63.35% percent or $4.39. At present, MEDS shares trade +13.31% above its 20-day simple moving average and +160.32% percent above its 100-day simple moving average. However, the stock is currently trading approximately +55.07% above its SMA50 and +2.25% above its SMA200.
Stochastic coefficient K was 36.51% and Stochastic coefficient D was 20.46%, while ATR was 1.54. Given the Stochastic reading of 67.38% for the 14-day period, the RSI (14) reading has been calculated as 67.12%. As of today, the MACD Oscillator reading stands at 1.07, while the 14-day reading stands at 1.08.
Analyst Ratings
TRxADE HEALTH Inc. (MEDS) has been rated Buy by analysts. According to 0 brokerage firms, MEDS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate TRxADE HEALTH Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $6.75, the current consensus forecast for the stock is $6.75 – $6.75. Based on these forecasts, analysts predict TRxADE HEALTH Inc. (MEDS) will achieve an average price target of $6.75.
